DE-LYCRA
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel industry, announced the launch of a revolutionary new targeted shaping innovation for stretch denim at a press conference at Kingpins Amsterdam today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424493653/en/
The LYCRA Company launches a revolutionary new targeted shaping innovation for stretch denim at Kingpins Amsterdam Spring 2024: LYCRA FitSense® denim technology. (Photo: Business Wire)
LYCRA FitSense® denim technology is a shaping technology engineered to provide a unique fit solution to consumers of all body types and shapes. Its advanced shaping effect delivers targeted support to common trouble spots that can impact garment fit, such as the tummy and waist, thighs and rear, offering a customizable fit solution that is a breakthrough for the denim industry.
“Targeted support is engineered into stretch jeans using our technology, new fabric construction, and precision garment making,” said Ebru Ozaydin, The LYCRA Company’s global strategic marketing director for denim, wovens, and ready-to-wear. “Our innovative solution is discreet and invisible, and jeans retain the authentic denim look and feel consumers love.”
Designers working for brands and garment makers will be able to take their craft to the next level by choosing where to shape, support, and lift, delivering a customized fit experience that will help consumers look and feel great in their jeans. This innovation also offers the potential to increase consumer satisfaction and reduce costly returns related to poor fit.
“The LYCRA® brand has consistently redefined what is possible, and our technologies continue to reshape the apparel industry,” said Steve Stewart, chief brand & innovation officer. “We’re thrilled to bring LYCRA FitSense® denim technology to market and look forward to showcasing it at Kingpins China in May and Kingpins New York in July.”
For the third consecutive year, the LYCRA® brand has teamed up with the House of Denim Foundation and Jean School students to mount the exhibition “Stretch Yourself #3: Denim of the Future, Designed by Gen Z.” Once again, talented student designers have created inspiring silhouettes that feature innovative fabrics from leading mills and powered by The LYCRA Company’s technologies.
Kingpins visitors can also learn more about the development of bio-derived LYCRA® fiber made with QIRA®. The LYCRA Company has teamed up with Qore®, the maker of QIRA®, to enable the world’s first large-scale commercial production of renewable elastane. Available in early 2025, this sustainable product will use field corn to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* and is expected to offer equivalent performance.
The LYCRA® brand is also celebrating 20 years of Kingpins Shows, including 10 years in Amsterdam, by sponsoring a happy hour at the end of the first day. DJ Red Planet will provide the soundtrack as memorable moments in the iconic brand's 65-year history flash on monitors. Opening remarks will recognize the elastane brand's status as the longest-standing sponsor of the show and the strong bond both companies share.
"A sure sign of success in life is who chooses to accompany you on the journey,” said Andrew Olah, Founder and CEO of Kingpins. “The LYCRA Company has been an amazing partner to so many in the jeans business and Kingpins has gained so much by our close relationship over two decades.”
To learn more about new LYCRA FitSense® denim technology, visit The LYCRA Company in the blue zone stand 11 at Kingpins Amsterdam, or lycra.com.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll US Consulting, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA® and LYCRA FitSense® are trademarks of The LYCRA Company.
Qore® and QIRA® are trademarks of Qore® LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424493653/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom